Key result
Intrathecal MVIIA and dexmedetomidine significantly altered cardiovascular responses to simulated haemorrhage, with MVIIA causing less vasoconstriction and a reduced increase in heart rate.
Why the study?
Do intrathecal dexmedetomidine or omega-conotoxins alter cardiovascular reflex responses to acute central hypovolaemia in rabbits?
Do intrathecal dexmedetomidine or omega-conotoxins alter cardiovascular reflex responses to acute central hypovolaemia in rabbits?
Intrathecal injections of MVIIA or dexmedetomidine may compromise cardiovascular compensatory responses to central hypovolemia, which could be clinically significant when used for chronic pain control.
May blunt compensatory reflexes during hypovolemia; hypothesis-generating for intrathecal use in chronic pain, needing human studies.
The effects of thoracic intrathecal doses (1 microg/kg) of the alpha2-adrenoceptor agonist dexmedetomidine and omega-conotoxins MVIIA and CVID on vasoconstrictor and heart rate responses to acute central hypovolaemia were studied in seven chronically instrumented rabbits. 2. Gradual inflation of an inferior vena cava cuff to reduce cardiac index (CI) by 8% per minute induced progressive vasoconstriction and an increase in heart rate (phase I). At approximately 40% of resting CI, there was sudden decompensation with failure of vasoconstriction and decrease in mean arterial pressure (MAP; phase II). 3. Both intrathecal MVIIA and CVID decreased resting CI (by 20% at 3 h), but only MVIIA significantly reduced resting MAP (P = 0.003). Dexmedetomidine resulted in transient bradycardia, but no other significant change in the resting circulation. With simulated haemorrhage, the relationship between CI and vascular conductance was shifted after MVIIA (1-3 h after injection) so that there was less vasoconstriction and a reduced increase in heart rate by the end of phase I compared with other treatments (P = 0.002 and P = 0.009, respectively). One hour after injection, dexmedetomidine reduced the slope of the phase I vasoconstrictor response (P = 0.03), but did not significantly alter the end-point of the response. With failure of vasoconstriction and the onset of phase II, vascular conductance was higher after MVIIA compared with controls. Both conotoxins caused progressive failure of vasoconstriction rather than recovery during phase II (P < 0.001). 4. Intrathecal injections of these drugs to control chronic pain may compromise cardiovascular responses to changes in central blood volume. At the single doses studied, there were significant differences between the responses to simulated haemorrhage after MVIIA or dexmedetomidine compared with CVID, with the prolonged effect after MVIIA most likely to be of clinical significance.
No takes yet. Share an insight, caveat, or question.
Blake et al. (2003) studied acute central hypovolaemia (n=7). intrathecal omega-conotoxins (MVIIA and CVID) or dexmedetomidine vs. controls was evaluated on vasoconstrictor and heart rate responses to acute central hypovolaemia. Intrathecal MVIIA and dexmedetomidine significantly altered cardiovascular responses to simulated haemorrhage, with MVIIA causing less vasoconstriction and a reduced increase in heart rate.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: